Literature DB >> 8530446

Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras.

C D Hu1, K Kariya, M Tamada, K Akasaka, M Shirouzu, S Yokoyama, T Kataoka.   

Abstract

The interaction between "switch I/effector domain" of Ha-Ras and the Ras-binding domain (RBD, amino acid 51-131) of Raf-1 is essential for signal transduction. However, the importance of the "activator domain" (approximately corresponding to amino acids 26-28 and 40-49) of Ha-Ras and of the "cysteine-rich region" (CRR, amino acids 152-184) of Raf-1 have also been proposed. Here, we found that Raf-1 CRR interacts directly with Ha-Ras independently of RBD and that participation of CRR is necessary for efficient Ras-Raf binding. Furthermore, Ha-Ras carrying mutations (N26G and V45E) in the activator domain failed to bind CRR, whereas they bound RBD normally. On the contrary, Ha-Ras carrying mutations in the switch I/effector domain exhibited severely reduced ability to bind RBD, whereas their ability to bind CRR was unaffected. Mutants that bound to either RBD or CRR alone failed to activate Raf-1. Ha-Ras without post-translational modifications, which lacks the ability to activate Raf-1, selectively lost the ability to bind CRR. These results suggest that the activator domain of Ha-Ras participates in activation of Raf-1 through interaction with CRR and that post-translational modifications of Ha-Ras are required for this interaction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530446     DOI: 10.1074/jbc.270.51.30274

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases.

Authors:  T Okada; C D Hu; T G Jin; K Kariya; Y Yamawaki-Kataoka; T Kataoka
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Phospholipase C(epsilon): a novel Ras effector.

Authors:  G G Kelley; S E Reks; J M Ondrako; A V Smrcka
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

Review 3.  Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.

Authors:  W Kolch
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

4.  Structural determinants of Ras-Raf interaction analyzed in live cells.

Authors:  Tzvetanka Bondeva; András Balla; Péter Várnai; Tamas Balla
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

5.  Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate.

Authors:  Pablo Rodriguez-Viciana; Celine Sabatier; Frank McCormick
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Association of yeast adenylyl cyclase with cyclase-associated protein CAP forms a second Ras-binding site which mediates its Ras-dependent activation.

Authors:  F Shima; T Okada; M Kido; H Sen; Y Tanaka; M Tamada; C D Hu; Y Yamawaki-Kataoka; K Kariya; T Kataoka
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

7.  Drosophila Raf's N terminus contains a novel conserved region and can contribute to torso RTK signaling.

Authors:  Jian Ding; Oren Tchaicheeyan; Linda Ambrosio
Journal:  Genetics       Date:  2009-12-14       Impact factor: 4.562

8.  The RafC1 cysteine-rich domain contains multiple distinct regulatory epitopes which control Ras-dependent Raf activation.

Authors:  M Daub; J Jöckel; T Quack; C K Weber; F Schmitz; U R Rapp; A Wittinghofer; C Block
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

9.  Modulation of KSR activity in Caenorhabditis elegans by Zn ions, PAR-1 kinase and PP2A phosphatase.

Authors:  John H Yoder; Huira Chong; Kun-Liang Guan; Min Han
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

Review 10.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.